glp 1 psoriasis Which PsO Patients Can Benefit From GLP-1RAs? GLP-1 agonists reduce psoriasis severity

Metastatic signet-ring melanoma in a patient with an unkown primary tumor

The clinical translation of these trial results, which will be important for the comparison of GLP-1RAs with SGLT2 inhibitors in the treatment of patients with heart failure and a preserved ejection fraction, remains to be determined

Protocol 4: nasal spray approach Goal: Needle-free administration with acceptable bioavailability trade-off Duration: 20 days active, then 4-6 months off Schedule: Days 1-20: 10-15 mg epitalon intranasally, divided into 2-3 daily doses Days 21-180: Off cycle Repeat 1-2 times per year Formulation: Reconstitute in saline with 3 percent DMSO for improved nasal absorption

R, Sadeghi M